U.S. Markets closed

Sorrento Therapeutics, Inc. (SRNE)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.75+0.05 (+2.94%)
At close: 4:00PM EDT
People also watch
NKRGLSTGTXADXSBLCM

Sorrento Therapeutics, Inc.

9380 Judicial Drive
San Diego, CA 92121
United States
858-210-3700
http://www.sorrentotherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees154

Key Executives

NameTitlePayExercisedAge
Dr. Henry H. Ji Ph.D.Co-Founder, CEO, Pres & Director800kN/A53
Mr. George K. Ng Esq., J.D.Exec. VP, Chief Admin. Officer & Chief Legal Officer551.49kN/A43
Dr. Jerome Bernard Zeldis M.D., Ph.D.Chief Medical Officer & Pres of Clinical Devel.103.13kN/A67
Mr. George UyConsultantN/AN/A61
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It develops therapeutic products for the treatment of auto-immune, inflammatory, neurodegenerative, and infectious diseases. The company offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain at end-stage disease. Its preclinical human therapeutic antibodies include antibody drug conjugates, bispecific approaches, and T-Cell Receptor, as well as Chimeric Antigen Receptor-T Cell (CAR-T) for adoptive cellular immunotherapy for the treatment of solid and liquid tumors. It is also involved in the development of T-007, an anti-CD38 CAR-T cellular therapy for the treatment of multiple myeloma, as well as for additional potential indications, such as amyloidosis and graft-versus-host disease; and T-009, an anti-CD123 CAR-T cellular therapy for the treatment of acute myelogenous leukemia. The company has license and collaboration agreement with Les Laboratoires Servier for the development, manufacture, and commercialization of products using its human immuno-oncology anti-PD-1 mAb STI-A1110. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Corporate Governance

Sorrento Therapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 9. The pillar scores are Audit: 10; Board: 5; Shareholder Rights: 9; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.